Patents Assigned to DIATHEVA S.R.L.
  • Publication number: 20210230292
    Abstract: The present invention relates to a multivalent, preferably bivalent, antibody complex, more preferably a diabody, i.e. a bivalent scFv, capable of recognizing and binding the human protein CD99, a composition comprising said complex and the use thereof for diagnostic purposes and/or for the treatment and/or the follow-up of leukaemias and/or myelodysplastic syndromes. Furthermore, the present invention relates to antibodies, preferably monoclonal, of the immunoglobulins G group type capable of recognizing and binding the human protein CD99, a composition comprising said immunoglobulins and the medical use thereof, in particular for the treatment and/or the follow-up of cancer, preferably solid tumours that express CD99 and/or leukaemias and/or myelodysplastic syndromes.
    Type: Application
    Filed: June 3, 2019
    Publication date: July 29, 2021
    Applicant: DIATHEVA S.R.L.
    Inventors: Valentina FIORI, Sabrina DOMINICI, Diego MORICOLI, Maria Elena LAGUARDIA, Cosimo Damiano CARBONELLA, Maria Cristina BALDUCCI
  • Patent number: 8822648
    Abstract: An anti-CEA scFv having an uncleaved Pel B leader sequence is surprisingly stable and is highly specific for CEA and CEACAM1.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: September 2, 2014
    Assignees: Instituto Superiore di Sanita, Diatheva s.r.l.
    Inventors: Maurizio Cianfriglia, Michela Flego, Alessandro Ascione, Valentina Fiori, Sabrina Domicini, Alessandra Mallano, Diego Moricoli, Silvia Zamboni
  • Publication number: 20130203964
    Abstract: An anti-CEA scFv having an uncleaved Pel B leader sequence is surprisingly stable and is highly specific for CEA and CEACAM1.
    Type: Application
    Filed: December 21, 2012
    Publication date: August 8, 2013
    Applicants: DIATHEVA S.R.L., INSTITUTO SUPERIORE DI SANITA
    Inventors: INSTITUTO SUPERIORE DI SANITA, DIATHEVA S.R.L.